Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 18 May 2022
Search results
603 results
-
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 23 November 2022
-
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
In development [GID-TA10427] Expected publication date: TBC
-
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
In development [GID-NG10110] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)
In development [GID-TA10366] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
In development [GID-TA10536] Expected publication date: TBC
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (Managed Access review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: 11 January 2023
-
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
In development [GID-HST10040] Expected publication date: TBC
-
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis
In development [GID-IPG10142] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Osteoporosis (postmenopausal women) - abaloparatide [ID882]
In development [GID-TA10071] Expected publication date: TBC
-
Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]
In development [GID-TA10923] Expected publication date: TBC
-
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention
In development [GID-IP1238] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: 31 May 2023
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
In development [GID-TA10179] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Implanting a baroreceptor stimulation device for resistant hypertension
In development [GID-IP1180] Expected publication date: TBC
-
Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]
In development [GID-TA10171] Expected publication date: TBC
-
Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]
In development [GID-TA10663] Expected publication date: 01 June 2022
-
Lifitegrast for treating dry eye disease [ID1229]
In development [GID-TA10196] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]
In development [GID-TAG479] Expected publication date: TBC
-
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]
In development [GID-TA10242] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: 16 November 2022
-
Personalised external aortic root support (PEARS) to prevent aortic root expansion and aortic dissection using mesh for people with Marfan syndrome
In development [GID-IPG10217] Expected publication date: TBC
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
In development [GID-TA10180] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
In development [GID-TA10775] Expected publication date: 10 August 2022
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC